NEW BioBiz Buzz EPISODE ALERT: “From the Horse’s Mouth — Inside Pharma’s Most Volatile Year”
What a year it’s been. Pharma’s first $1 trillion company. A $400 billion collapse. Mass layoffs, geopolitical upheaval, AI valuations soaring, and a regulatory reset that changes everything for rare disease developers.
In this unmissable episode of #BioBizBuzz, host Jo Shorthouse sits down with Mike Ward, Clarivate’s Global Head of Life Sciences & Healthcare Thought Leadership, fresh from his “Winners & Losers” keynote at One Nucleus’s 25th Genesis conference in London.
Together they unpack 2025’s defining stories:
- Eli Lilly’s meteoric rise to trillion-dollar status
- Novo Nordisk’s dramatic fall from grace
- Pfizer’s $10B Metsera move and what it signals for obesity R&D
- China’s transformation into an innovation powerhouse
- The FDA’s game-changing “Plausible Mechanism Pathway” for ultra-rare diseases
- Why pharma M&A hasn’t roared back—yet
If you’ve been wondering who really won (and lost) in the industry’s most turbulent year on record, this is the one episode you can’t miss.
Listen now wherever you get your podcasts — or catch the full transcript and Genesis presentation highlights at Clarivate and One Nucleus.